

FY2022 Financial Results

May 11, 2023 Santen Pharmaceutical Co., Ltd.



■ Featuring







FY2022 Financial Results

Takeshi Ito President & Chief Executive Officer

Rie Nakajima Chief Operating Officer

Kazuo Koshiji Chief Financial Officer & Chief Risk Officer Peter Sallstig Chief Medical Officer



Forward-looking statements

- Materials and information provided in this announcement include so-called "forward-looking statements" .The earnings forecasts and other forward-looking statements herein are based on information currently available to the Company and certain assumptions that we believe to be reasonable. The realization of these forecasts is subject to various risks and uncertainties. Please be aware that actual results could differ materially from these forward-looking statements. We assume no obligation to update the contents of this document from time to time.
- Risk factors include, but are not limited to, the following: External factors such as trends in pharmaceutical administration, social and economic conditions, changes in laws and regulations, and exchange rates. Changes in the competitive environment, such as the impact of generics. Reliance on certain products and business partners, such as dependence on mainstay products, reliance on licensed products, and reliance on certain business partners for the supply of bulk drugs. Uncertainty in the development of new drugs, the possibility that R&D investment will not produce sufficient results, the success or failure of alliances with other companies, and other R&D activities. Other factors include intellectual property rights, production slowdowns and delays caused by natural disasters, product supply issues such as discontinuations and product recalls, litigation, and risks related to global business development.
 - This document contains information about pharmaceutical products (including products under development) but is not intended for advertising or medical advice.
- The purpose of this document is to disclose information that serves as a reference to investors, and it does not constitute a solicitation or recommendation for investment. You should make investment decisions based on your own judgment.
- The information contained in this document is subject to change without notice. The use of these materials is the responsibility of the user, and we assume no responsibility for any damages caused by the use of these materials, including errors in the stated information.

CORE PRINCIPLE and WORLD VISION

CORE PRINCIPLE

天機に参与する

Tenki ni sanyo suru

"Exploring the secrets and mechanisms of nature in order to contribute to people's health" *

WORLD VISION

Happiness with Vision

The Happiest Life for every individual, through the Best Vision Experience

* Santen's original interpretation of a passage from the Zhongyong (The Doctrine of the Mean) by Confucius.





FY2022 Financial Results

Agenda

1. Overview

- 2. FY2022 Financial Results
- 3. FY2023 Outlook
- 4. R&D Update



Summary

Profitability improvements and mid-to-long term growth initiatives in play FY2023 focus: solid recovery in profitability

FY2022 Consolidated results

Revenue: JPY 279.0 billion (+5% YoY) Core OP: JPY 44.2 billion (-5% YoY), Core OP ratio: 16%

Initiatives for mid-to-long term regrowth

- Profitability improvement: Plan to complete streamlining of Americas in H1 FY2023 Contribution profit: FY2023 FCST JPY -1.1 billion, improved 3.4 billion YoY (FY2022: -4.5 billion) Regional profit: FY2023 FCST JPY -3.1 billion, improved 4.8 billion YoY (FY2022: -7.9 billion)
- Growth pillars: Promote initiatives to expand commercial excellence to overseas Solid investment on R&D for future growth

FY2023 Consolidated forecasts

Revenue: JPY 273.0 billion (-2% YoY) Core OP: JPY 46.0 billion (+4% YoY), Core OP ratio: 17%

Shareholder returns

FY2022: Annual dividend of JPY 32, JPY 25.7 billion of share buyback

FY2023: Annual dividend forecast of JPY 32, resolved JPY 24.5 billion (maximum) of share buyback (from May 12, 2023 to March 22, 2024)





FY2022 Financial Results

Agenda

- 1. Overview
- 2. FY2022 Financial Results
- 3. FY2023 Outlook
- 4. R&D Update



Strong sales in fourth quarter mainly from Japan mainstay products absorbed impact from China

(JPY billions)	FY2	021	FY2022							
	Actual	vs Revenue	Actual	vs Revenue	YoY	Forecast (Feb.7)	vs forecast			
Revenue	266.3	-	279.0	-	+4.8%	272.0	103%			
Cost of sales	109.7	41%	113.0	40%	+3.0%	111.0	102%			
Gross Profit	156.6	59%	166.1	60%	+6.1%	161.0	103%			
SG&A expenses	83.9	31%	93.5	34%	+11.6%	90.5	103%			
R&D expenses	26.4	10%	28.3	10%	+7.3%	29.5	96%			
Core operating profit	46.3	17%	44.2	16%	-4.5%	41.0	108%			
Non core SG&A expense	0.6	0%	2.7	1%	+324.9%	7.5	36%			
Amortization on intangible assets associated with products	9.7	4%	9.5	3%	-2.2%	9.3	102%			
Other income	1.0	0%	3.5	1%	+238.0%	0.7	542%			
Other expenses	1.1	0%	38.6	14%		31.3	123%			
Operating profit	35.9	13%	-3.1	-	-	-6.5	48%			
Finance income	2.5	1%	1.2	0%	-54.7%	1.3	89%			
Finance expenses	1.2	0%	1.5	1%	+24.0%	1.0	150%			
Share of loss of Investments accounted for using equity method	1.6	1%	2.4	1%	+47.2%	2.3	103%			
Profit before tax	35.6	13%	-5.8	-	-	-8.5	68%			
Income tax expenses	8.4	3%	9.2	3%	+9.0%	7.0	131%			
Actual tax ratio	23.7%	-	-		-	-	-			
Net profit	27.2	10%	-15.0	-	-	-15.5	97%			
ROE	8.4%		-							
Core ROE	10.9%		10.5%							
Core net profit	35.2	13%	33.2	12%	-5.6%	30.8	108%			

	FY2021	FY2022
	ACT	ACT
JSD (JPY)	112.57	135.40
EUR (JPY)	130.75	140.97
CNY (JPY)	17.55	19.72

Gross Profit

<u>+4.8% YoY</u>

- Revenue: Increased mainly from stronger sales of mainstay products including *Alesion* products coupled with positive FX impact (JPY+9.4bil)
- COGS ratio: Decreased to 40% resulting from product mix, despite of one-time costs.
- Gross profit: Impacted JPY+7.0bil by FX

Operating Profit (Core basis)

<u>-4.5% YoY</u>

 Exceeded forecast on Feb 7, 2023 (Q3), from strong revenue, COGS ratio improvement and cost optimization, despite increase in R&D, personnel costs and other expenses including FX negative impacts

Operating Profit (IFRS)

 Mainly due to the impairment loss (Eyevance: JPY 30.1bil, STN10109: JPY 3.1bil) and expenses related to regrowth including Americas streamlining (total: JPY 4.8bil)


Net Profit (IFRS)

 Increased income tax expenses. Tax rate excluding onetime factor : 24.9%



FY2022 Sales bridge

Japan, Asia and EMEA outperform expectations and contribute to revenue growth




Americas +28.5% YoY (Ex. FX impact +9.5%): Increased revenue including FX impact, but profitability remains an issue. Maximized streamlining decided

Santen

8

FY2022 Core operating profit bridge

Gross profit improved from sales growth. Core OP impacted from expenses including FX. Cost optimization progresses as expected



Gross profit	Net +9.5bil YoY. Increased revenue (incl. FX impact) and decrease in COGS ratio (-0.7pt YoY) from region/product mix
SG&A	Net -9.7bil YoY. Negatively impacted by increase in sales-linked-costs and overseas expenses including FX impact (SG&A ratio: +2.0pt YoY)
R&D	Net -1.9bil YoY. Impacted from weaker JPY. Foreign currency comprises 60% (R&D expenses ratio: +0.2pt YoY)





FY2022 Financial Results

Agenda

- 1. Overview
- 2. FY2022 Financial Results
- 3. FY2023 Outlook
- 4. R&D Update



Decrease in revenue from GE impact in Japan

FY2022 FY2023 ACT FCST 135.40 USD (JPY) 130.00 EUR (JPY) 140.97 140.00 CNY (JPY) 19.72 19.00 **Core OP increase from profitability improvement initiatives**

(JPY billions)	FY2	022			
	Actual	vs Revenue	Forecast	vs Revenue	YoY
Revenue	279.0	-	273.0	-	-2.2%
Cost of sales	113.0	40%	111.0	41%	-1.7%
Gross profit	166.1	60%	162.0	59%	-2.5%
SG&A expenses	93.5	34%	87.0	32%	-7.0%
R&D expenses	28.3	10%	29.0	11%	+2.5%
Core operating profit	44.2	16%	46.0	17%	+4.0%
Non core SG&A expense	2.7	1%	0.8	0%	-70.5%
Amortization on intangible assets associated with products	9.5	3%	9.4	3%	-1.2%
Other income	3.5	1%	0.6	0%	-83.0%
Other expenses	38.6	14%	4.4	2%	-88.6%
Operating profit	-3.1	-	32.0	12%	-
Finance income	1.2	0%	1.0	0%	-13.2%
Finance expenses	1.5	1%	0.8	0%	-46.6%
Share of loss of Investments accounted for using equity method	2.4	1%	2.4	1%	+1.6%
Profit before tax	-5.8	-	29.8	11%	-
Income tax expenses	9.2	3%	7.4	3%	-19.4%
Actual tax ratio	-	-	25%	-	-
Net profit	-15.0	-	22.4	8%	-
ROE	-		8%		
Core ROE	10.5%		12%		
Core net profit	33.2	12%	34.5	13%	+3.8%

Gross Profit

-2% YoY

- Revenue: Impact from GE erosion of mainstay products in Japan
- COGS ratio: Inflation impact but maintain same level as FY2022 (FY2022: 40.5%, FY2023: 40.7%)

Operating Profit (Core basis)

+4% YoY

- Increase allocation to R&D expenses from FY2022
- Decrease in SG&A expenses ratio from progress in profitability improvement initiatives (SG&A ratio: -2pt vs FY2022)

Operating Profit (IFRS)

JPY32.0 billion, reflecting structural reform costs


Net Profit (IFRS)

Tax ratio: 25%. Decrease income tax expenses from FY2022. Expect net profit of JPY 22.4 billion



FY2023 Sales outlook bridge


Stable growth from overseas



Santen

FY2023 Core OP outlook bridge

Allocation to R&D expenses for mid-to-long term growth Core OP increase from profitability improvement initiatives progress




Gross profit	Net - 4.1bil YoY. Mainly due to decrease of revenue (COGS ratio: +0.2pt YoY)
SG&A	Net +6.5bil YoY. Companywide promotion of cost optimization initiatives (SG&A ratio: -1.7pt YoY)
R&D	Net -0.7bil YoY. Allocate sufficient R&D expenses for future growth (R&D expenses ratio: +0.5pt YoY)



Shareholder returns

Annual dividend forecast of JPY 32 (JPY 16 interim & year-end) JPY 24.5 billion (maximum) share buyback







FY2022 Financial Results

Agenda

- 1. Overview
- 2. FY2022 Financial Results
- 3. FY2023 Outlook
- 4. R&D Update



Q4 FY2022 R&D update

Progress across both Existing area contributing to growth and New area with scalability expected after FY2026

	STN10 139 00 Rhopressa®/Rhokiinsa®	Glaucoma	Launched in Europe (Sweden)
	STN1011101 <i>TAPCOM / TAPTIQOM</i>	Glaucoma	Filed in China
Existing area	STN1012600 Sepetaprost	Glaucoma	Achieved LPO ¹ in P3 trial in Japan
	STN1008903 Diquas LX	Dry eye	Filed in Asia (South Korea)
	STN1011402 Epinastine HCI (ophthalmic cream)	Allergic conjunctivitis	Filed in Japan
New area	STN1012700 Atropine sulfate	Myopia	Achieved LPI^2 in P2/3 trial in China
	STN1013600 Ursodeoxycholic acid	Presbyopia	Achieved LPI in P2a trial in US

1. LPO; Last Patient Out. 2. LPI; Last Patient In.



FY2023 main events

Enhanced product lineup in China/Asia PJ data readouts including pivotal study for myopia treatment

		Data readout	Approval	Launch
	Glaucoma	STN10 126 00 P3 (Japan)	STN10 130 01 (Europe)	STN10 139 00 (<i>Rhopressa</i> , Asia)
g	Gladcollia	P2exploratory study (Europe)		STN10 140 00 (<i>Rocklatan</i> , Asia)
Existing area	Dry eye	STN10 141 00 P1/2a (Japan)	STN10 089 03 (Asia)	STN10 005 01 (<i>Cationorm</i> , China)
EXi	Allergy		STN10 114 02 (Japan)	STN10 076 03 (<i>Verkazia</i> , China)
	Infectious diseases			STN10 001 01 (<i>Ducressa</i> , Asia)
area	Муоріа	STN10 127 00 P2/3 (Japan)		
New	Presbyopia	STN10 136 00 P2a (US)		





FY2022 Financial Results

Appendix



Copyright© 2023 Santen All rights reserved.


FY2022 Consolidated results

COGS ratio decreased in H2 mainly due to product mix change Despite sales-linked-expenses increase, costs controlled as expected

(JPY billions)			FY2	2021							FY2022	2			
	H1 Actual	vs Revenue	H2 Actual	vs Revenue	FY Actual	vs Revenue	H1 Actual	vs Revenue	H2 Actual	vs Revenue	FY Actual	vs Revenue	YoY	Forecast (Feb.7)	vs Revenue
Revenue	128.8	-	137.5	-	266.3	-	128.9	-	150.1	-	279.0	-	+5%	272.0	-
Cost of sales	52.9	41%	56.8	41%	109.7	41%	55.9	43%	57.0	38%	113.0	40.5%	+3%	111.0	40.8%
Gross profit	75.9	59%	80.7	59%	156.6	59%	73.0	57%	93.1	62%	166.1	59.5%	+6%	161.0	59.2%
SG&A expenses	39.2	30%	44.6	32%	83.9	31%	42.3	33%	51.3	34%	93.5	33.5%	+12%	90.5	33.3%
R&D expenses	12.3	10%	14.0	10%	26.4	10%	14.3	11%	14.0	9%	28.3	10.1%	+7%	29.5	10.8%
Core operating profit	24.3	19%	22.0	16%	46.3	17%	16.5	13%	27.8	19%	44.2	15.9%	-5%	41.0	15.1%
Non core SG&A expense	0.4	0%	0.2	0%	0.6	0%	-	-	2.7	2%	2.7	1.0%	+325%	7.5	2.8%
Amortization on intangible assets associated with products	4.8	4%	4.9	4%	9.7	4%	5.2	4%	4.4	3%	9.5	3.4%	-2%	9.3	3.4%
Other income	0.2	0%	0.8	1%	1.0	0%	0.3	0%	3.3	2%	3.5	1.3%	+238%	0.7	0.2%
Other expenses	0.5	0%	0.6	0%	1.1	0%	30.6	24%	8.1	5%	38.6	13.8%		31.3	11.5%
Operating profit	18.8	15%	17.1	12%	35.9	13%	-19.0	-	15.9	11%	-3.1	-	-	-6.5	-
Finance income	0.7	1%	1.9	1%	2.5	1%	1.2	1%	-0.1	-	1.2	0.4%	-55%	1.3	0.5%
Finance expenses	0.4	0%	0.8	1%	1.2	0%	0.3	0%	1.2	1%	1.5	0.5%	+24%	1.0	0.4%
Share of loss of investments accounted for using equity method	0.6	0%	1.0	1%	1.6	1%	1.1	1%	1.3	1%	2.4	0.8%	+47%	2.3	0.8%
Profit before tax	18.4	14%	17.2	13%	35.6	13%	-19.1	-	13.3	9%	-5.8	-	-	-8.5	-
Income tax expenses	4.1	3%	4.3	3%	8.4	3%	2.9	2%	6.3	4%	9.2	3.3%	+9%	7.0	2.6%
Net profit	14.3	11%	12.9	9%	27.2	10%	-22.0	-	7.0	5%	-15.0	-	-	-15.5	-
Core net profit	18.6	14%	16.6	12%	35.2	13%	12.5	10%	20.8	14%	33.2	11.9%	-6%	30.8	11.3%




Revenue and contribution profit by region



Copyright© 2023 Santen All rights reserved.



FY2022 revenue by region




Santen 21


43%

1%

Healthy financial position maintained




Cash flow





Cash flow

Stable cash generation



EBITDA = (Operating Profit) – (Other Income) + (Other expenses) + (Depreciation)


Copyright© 2023 Santen All rights reserved.

red. Cash conversion Cycle: Based on turnover period of trade and other receivables, inventories, and business operation related expenses



24

Core ROE, ROE and ROIC



Foreign exchange rate assumptions and sensitivities

FX rate	<u>e</u>				(JPY)
	FY2021 Actual	FY2022 Actual	FY2022 Forecast (Feb. 7)	FY2022 Actual vs Forecast	FY2023 Forecast
USD	112.57	135.40	140.00	96.7%	130.00
EUR	130.75	140.97	140.00	100.7%	140.00
CNY	17.55	19.72	20.00	98.6%	19.00

Sensitivities

Impact of a 1% depreciation of the yen (vs FY2023 forecast rate) (JPY billions)								
Total* USD								
+1.0	+0.03	+0.5	+0.28					
+0.1	-0.11	+0.06	+0.06					
+0.0	-0.13	+0.04	+0.04					
	t rate) Total* +1.0 +0.1	t rate) Total* USD +1.0 +0.03 +0.1 -0.11	t rate) (J Total* USD EUR +1.0 +0.03 +0.5 +0.1 -0.11 +0.06					

FX impact on FY2022 (vs FY2021)


	(JPY billions)
	Total
Revenue	+9.4
Core OP	-0.6
OP (IFRS)	-6.3

*Total: impacts from USD, EUR, CNY and other major currencies (rounding to nearest 100 million)



Segment: Market size Graph: Market share (change from last year)

Prescription Ophthalmic Market in Japan (Apr. 2022 - Mar. 2023)



Copyright© 2023 Santen All rights reserved.



Current status of global development (1)

Glaucoma and ocular hypertension area

Indication	Generic Name	Contractual territory	Dev. Code		Development Status ¹
	Tafluprost / timolol maleate (combination) TAPCOM / TAPTIQOM	Japan, China Asia, Europe	STN10 111 01 DE-111A	China	Filed in December 2022 <i>Plan: FY2024 approval</i>
	Omidenepag			US	Approved
	isopropyl EYBELIS / OMLONTI	WW ²	STN10 117 00 DE-117	Japan	Launched
				Asia	Launched
Glaucoma	Sepetaprost	WW		US	P2 (met primary endpoint)
			STN10 126 00 DE-126	Japan	P3 Plan: FY2023 P3 completion
				Europe	P2 (exploratory study) completion, analysis in progress
		WW (In house)		Japan	Launched (soft launch)
	Implant device PRESERFLO MicroShunt	(In-house) *Excl. Americas, Australia, New Zealand	STN 20001 00 DE-128	Europe	Launched
				Asia	Launched

1. Only projects where the study protocols were approved in-house are shown, 2. Worldwide



Current status of global development (2)

Glaucoma and ocular hypertension area

Indication	Generic Name	Contractual territory	Dev. Code	Development Status	
	Latanoprost	WW (In-house)	STN10 130 01 DE-130A Catioprost	Europe	Filed <i>Plan: FY2023 approval</i>
	Latanoprost			Asia	P3 (met primary endpoint)
			STN10 139 00 AR-13324	Japan	P3 <i>Plan: FY2024 P3 completion</i>
Glaucoma	Netarsudil mesilate Rhopressa®/Rhokiinsa®	Japan, China Asia, Europe		Europe	Launched in February 2023
				Asia	Approved <i>Plan: FY2023 launch</i>
	Netarsudil mesilate /latanoprost (combination) _{Rocklatan[®]/Roclanda[®]}	Japan, China Asia, Europe	STN10 140 00 PG-324	Europe	Launched
				Asia	Approved Plan: FY2023 launch

Current status of global development (3)

Keratoconjunctival disease area including dry eye

Indication	Generic Name	Contractual territory	Dev. Code		Development Status	
Vernal	Ciclosporin Verkazia	WW (In-house)	STN10 076 03	US	Launched	
keratoconjunc- tivitis			DE-076C	China	Approved Plan: FY2023 launch	
	Diquafosol sodium	Japan, China Asia, Europe	STN10 089 03	Japan	Launched	
Dry eye	(long-lasting) Diquas LX		DE-089C	Asia	Filed in March 2023 <i>Plan: FY2023 approval</i>	
	Olodaterol hydrochloride	WW	STN10 141 00	Japan	P1/2a Plan: FY2023 P1/2a completion	
Fuchs endothelial corneal dystrophy	Sirolimus (eye drop)	1	STN10 109 04 ¹	US France India	P2a Plan: FY2025 P2a completion	
Meibomian gland dysfunction	Sirolimus (eye drop)	WW (In-house)	STN10 109 05	Japan	P2a (not met primary/secondary endpoints. But observed efficacy on some exploratory endpoints and detailed analysis in progress)	
Allergic conjunctivitis	Epinastine HCI (ophthalmic cream)	Japan	STN10 114 02	Japan	Filed in March 2023 <i>Plan: FY2023 approval</i>	

1 Santen retains the option right for exclusive license of this program. Santen development code to be formally assigned to the product when Santen obtains exclusive license upon the completion of Phase II trial.



Current status of global development (4)

Refractive error

Indication	Generic Name	Contractual territory	Dev. Code		Development Status
	Atropine sulfate	Japan, China Asia	STN10 127 00 DE-127	Japan	P2/3 Plan: FY2023 P2/3 completion
				China	P2/3 Plan: FY2026 P2/3 completion
Myopia				Asia	P2 (met primary endpoint)
wyopia		EMEA	STN10 127 01 SYD-101	Europe	P3 (conducted by Sydnexis Inc.) Plan: FY2024 P3 completion
	AFDX0250BS	WW	STN10 134 00	Japan	P1 (confirmed safety and tolerability) Plan: FY2023 P2a start
				China	Plan: FY2023 P1 start
Presbyopia	Ursodeoxycholic acid	WW (In-house)	STN10 136 00	US	P2a Plan: FY2023 P2a completion
				Japan	P1 (confirmed safety and tolerability)



Current status of global development (5)

Others

Indication	Generic Name	Contractual territory	Dev. Code		Development Status
	Oxymetazoline hydrochloride	Japan, China Asia, EMEA Canada	STN10 138 00 RVL-1201	Japan	P3 Plan: FY2024 P3 completion
Ptosis				China	Plan: FY2023 P3 start
				Asia	Plan: Considering filing after FY2023
Retinitis pigmentosa	jCell	Japan, China Asia, Europe	STN 60001 00	-	P2 safety study (US, conducted by jCyte, Plan to complete in FY2022). Considering P3 plan



Expected launch schedule

	: LCM products : Drug with a new active ingredient/Medical device	ug with a new active FY2023		FY2024		FY2025		FY2026~	
a1		Rhopressa Asia	Rocklatan Asia	Taptiqom CN	Catioprost EMEA	Rhopressa JP	Catioprost Asia	Eybelis PFUD ⁵ CN	Roclanda PFMD EMEA
	Glaucoma			Eybelis PFUD Asia		STN10 126 00 JP		STN10 126 00 CN, EMEA	MicroShunt CN
g area ¹								Catioprost PFMD ⁶ EMEA	Rocklatan JP
Existing	Dry eye	Cationorm CN		Diquas LX Asia				Diquas LX CN	STN10 141 00 Worldwide (WW)
Ê	Allergy	Verkazia CN		Alesion LX Asia	Alesion Cream				
	Infectious diseases	Ducressa Asia		Alesion is a registered trademark of Boehringer Ingelheim KG					
New area ²	Муоріа					STN10 127 00 JP	STN10 12701 EMEA	STN10 127 00 CN, Asia	STN10 134 00 WW
	Ptosis							STN10 138 00 JP, CN, Asia, EMEA	
	Presbyopia							STN10 136 00 WW	
	FECD ³							STN10 10904 ⁷ (FECD)	
	MGD ⁴							STN10 10905 (MGD) WW	
	Retinitispigmentosa							jCell JP, CN, Asia, EMEA	

The pipelines listed here are only those for which disclosure has been agreed upon with each partner company. Not all planned pipelines or development regions are specified. The schedule is based on the best-case scenario assumed as of March 31, 2023, and does not guarantee launch. 1. Disease areas where our existing products already obtained indications. 2. Disease areas where there are no existing Santen products on the market with indications. 3. Fuchs Endothelial Corneal Dystrophy 4. Meibomian Gland Dysfunction 5. Preservative Free Unit Dose 6. Preservative Free Multi Dose 7. Santen holds the exercise option for exclusive implementation rights for this program. This project code is a planned code number that will be assigned after Santen obtains exclusive implementation rights upon completion of Phase II clinical trials.



FY2022 R&D summary

	~Phase 2	Phase 3/filing	Approval/launch	
	STN1014100 P1/2a start (Japan)	STN1011101 filing (China)	STN1011702 launch (Japan)	
		STN1013001 filing (Europe)	STN2000100 launch (Japan, Asia)	
Existing area		P3 completion (Asia)	STN10 139 00 launch (Europe)	
Glaucoma		STN10 126 00 P3 start (Japan)	approval (Asia)	
Dry eye		STN1008903 filing (Asia)	STN1014000 launch (Europe)	
Allergy etc.		STN10 114 02 filing (Japan)	approval (Asia)	
			STN1011700 approval (US)	
			STN1008903 launch (Japan)	
			STN10 076 03 launch (US) approval (China)	
New area Refractive error	STN10 109 04 ³ P2a start (US, France, India)		STN1000501 approval (China)	
Ptosis FECD ¹	STN1010905 P2a completion (Japan)		Glaucoma/ocular hypertension Keratoconjunctival disease area	
MGD ² etc.	STN10 136 00 P2a start (US)	STN10 138 00 P3 start (Japan)	including dry eye	
	P1 completion (Japan)	STN1012700 P2/3 start (China)	Refractive error Others	

1. Fuchs Endothelial Corneal Dystrophy 2. Meibomian Gland Dysfunction 3. Santen retains the option right for exclusive license of this program. Santen development code to be formally assigned to the product when Santen obtains exclusive license upon the completion of Phase II trial.



